Tying it all Together

Riddle MC Making the transition from oral to insulin therapy. Am J Med.2005;118(suppl 5A):14S-20S.

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med.2005;353: 2643-2653.

Gerstein HC , Rosenstock J. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?Endocrinol Metab Clin North Am. 2005;34:137-154.

Nathan DM , Buse JB , Davidson MB , et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care.2006;29: 1963-1972.

Blonde L. , Klein EJ , Han J. , et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med.2005;143:559-569.

Monnier L. , Lapinski H. , Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care.2003;26:881-885.

Polonsky WH , Fisher L. , Guzman S. , Villa-Caballero L. , Edelman SV Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-2545.

Polonsky WH , Jackson RA What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22:147-150.

Peyrot M. , Rubin RR , Lauritzen T. , et al, on behalf of the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care.2005;28:2673-2679.

Korytkowski M. , Niskanen L. , Asakura T. FlexPen®: addressing issues of confidence and convenience in insulin delivery. Clin Ther.2005;27(suppl 2): S89-S100.

Rosenstock J. , Cappelleri JC , Bolinder B. , Gerber RA Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care.2004;27:1318-1323.

Berlowitz DR , Ash AS , Glickman M. , et al. Developing a quality measure for clinical inertia in diabetes care. Health Serv Res.2005;40(6 pt 1):1836-1853.

Brown JB , Nichols GA , Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.

Riddle MC , Rosenstock J. , Gerich J. , on behalf of the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care.2003;26: 3080-3086.

Zimmerman BR , ed. Medical Management of Type 2 Diabetes4th ed, Clinical Education Series. Alexandria, Va: American Diabetes Association; 1998.

Riddle MC Timely initiation of basal insulin. Am J Med.2004;116(suppl 3A):3S-9S.

Walsh J. , Roberts R. Pumping Insulin. 4th ed. San Diego, Calif: Torrey Pines Press; 2006.